tiprankstipranks
Trending News
More News >
ABIONYX Pharma SA (FR:ABNX)
:ABNX
Advertisement

ABIONYX Pharma SA (ABNX) AI Stock Analysis

Compare
5 Followers

Top Page

FR:ABNX

ABIONYX Pharma SA

(LSE:ABNX)

Select Model
Select Model
Select Model
Neutral 52 (OpenAI - 4o)
Rating:52Neutral
Price Target:
€2.00
▼(-40.83% Downside)
ABIONYX Pharma SA's overall stock score is moderate, primarily influenced by its challenging financial performance and valuation concerns. While technical analysis shows some positive momentum, the underlying financial and valuation issues pose significant risks. The lack of earnings call data and notable corporate events further limits the assessment.

ABIONYX Pharma SA (ABNX) vs. iShares MSCI France ETF (EWQ)

ABIONYX Pharma SA Business Overview & Revenue Model

Company DescriptionABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. It has a strategic partnership with GTP Biologics and VBI Therapeutics Group for the bioproduction of the bio-HDL in France. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.
How the Company Makes MoneyABIONYX Pharma generates revenue primarily through the development and commercialization of its pharmaceutical products. The company makes money by advancing its product candidates through various stages of clinical trials and subsequently licensing or partnering with larger pharmaceutical companies for further development and market access. Key revenue streams include milestone payments from partnerships, royalties on product sales once commercialized, and potential upfront payments from licensing agreements. Additionally, the company may benefit from government grants and funding aimed at supporting innovative biopharmaceutical research.

ABIONYX Pharma SA Financial Statement Overview

Summary
ABIONYX Pharma SA's financial performance is concerning, with declining revenues, persistent losses, and liquidity issues. The income statement shows a negative EBIT margin of -97.83% and net profit margin of -95.65%. The balance sheet indicates moderate leverage but poor profitability with a negative return on equity of -59.28%. Cash flow analysis reveals negative free cash flow, underscoring liquidity challenges.
Income Statement
35
Negative
ABIONYX Pharma SA's income statement indicates significant challenges. The company experienced a decline in revenue by 0.86% from 2023 to 2024, and gross profit margin stands at a low 19.57% for 2024, reflecting high cost relative to revenue. The company also reported a negative EBIT margin of -97.83% and a net profit margin of -95.65%, highlighting ongoing operational inefficiencies and substantial losses.
Balance Sheet
50
Neutral
The balance sheet shows moderate financial health, with a debt-to-equity ratio of 0.37, suggesting manageable leverage. However, the equity ratio is 55.20%, indicating a fair level of reliance on equity financing. Return on equity is negative at -59.28%, reflecting the company's unprofitable operations.
Cash Flow
40
Negative
The cash flow statement reveals negative free cash flow and operating cash flow, indicating potential liquidity issues. The free cash flow to net income ratio is 0.82, suggesting cash flow challenges relative to net losses. Additionally, there is a slight improvement in operating cash flow to net income ratio from -1.05 in 2023 to -0.82 in 2024, yet it remains negative.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue4.38M4.60M4.64M5.25M675.00K0.00
Gross Profit827.00K844.00K618.00K636.00K259.00K-80.00K
EBITDA-226.50K-4.93M-4.84M-4.01M-7.42M-2.33M
Net Income-4.59M-4.40M-3.52M-4.21M-5.82M-1.89M
Balance Sheet
Total Assets12.98M13.45M14.83M15.82M21.83M10.29M
Cash, Cash Equivalents and Short-Term Investments3.38M3.23M4.10M4.05M7.93M9.15M
Total Debt4.12M2.76M3.39M4.01M4.96M24.00K
Total Liabilities7.56M6.03M6.91M8.65M11.15M3.66M
Stockholders Equity5.41M7.42M7.92M7.17M10.68M6.63M
Cash Flow
Free Cash Flow-3.40M-3.60M-3.83M-3.53M-6.86M-747.00K
Operating Cash Flow-3.43M-3.60M-3.70M-3.36M-6.69M-599.00K
Investing Cash Flow-209.00K-100.00K-130.00K-175.00K1.34M-125.00K
Financing Cash Flow1.74M2.80M3.89M-194.00K3.97M1.55M

ABIONYX Pharma SA Technical Analysis

Technical Analysis Sentiment
Positive
Last Price3.38
Price Trends
50DMA
3.22
Positive
100DMA
2.28
Positive
200DMA
1.76
Positive
Market Momentum
MACD
0.03
Positive
RSI
48.66
Neutral
STOCH
54.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ABNX, the sentiment is Positive. The current price of 3.38 is below the 20-day moving average (MA) of 3.50, above the 50-day MA of 3.22, and above the 200-day MA of 1.76, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 48.66 is Neutral, neither overbought nor oversold. The STOCH value of 54.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ABNX.

ABIONYX Pharma SA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
€117.11M-62.40%-10.91%-25.57%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
50
Neutral
€24.40M101.95%35.55%
46
Neutral
€18.52M
45
Neutral
€44.25M-33.26%59.05%57.39%
41
Neutral
€23.69M-92.35%63.25%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:ABNX
ABIONYX Pharma SA
3.38
2.14
172.58%
FR:POXEL
Poxel SA
0.37
0.06
18.21%
FR:SIGHT
GenSight Biologics SA
0.13
-0.18
-58.41%
FR:ALDVI
Advicenne SA
1.70
-0.19
-9.97%
FR:ALVAL
Valbiotis SA
0.78
-0.60
-43.46%
FR:ALGAE
Fermentalg SA
0.49
0.14
40.74%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 05, 2025